Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- context label "Adults" assertion.
- association label "Clinician's annotation: “Menopausal syndrome—given smoking and hyperlipidemia, we will try nonhormonal options. Rx prozac”" assertion.
- context label "Adults" assertion.
- association label "Clinician's annotation: “Pt was told to continue Lexapro. RX options for her constipation were reviewed”" assertion.
- context label "Adults" assertion.
- association label "Clinician's annotation “bmi 37.5, discussed wt loss surgery and drugs, on anafranil (Clomipramine)”" assertion.
- context label "adults" assertion.
- association label "Cyclobenzaprine is frequently used off-label in fibromyalgia and is associated with improved pain, sleep, and fatigue in several studies." assertion.
- context label "adults" assertion.
- association label "Tension-type headache (TTH) is the most common primary headache disorder, with a worldwide lifetime prevalence of 46% to 78%. (...) Amitriptyline is recommended as a first-line drug for prophylaxis. (This is an off-label use of amitriptyline)." assertion.
- context label "adults" assertion.
- association label "Off-label ketamine treatment has shown acute antidepressant effects that offer hope for patients with therapy-resistant depression. However, its potential for integration into treatment algorithms is controversial, not least because the evidence base for maintenance treatment with repeated ketamine administration is currently weak. Ketamine is also a drug of misuse, which has raised concerns regarding the target population." assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- context label "adults" assertion.
- association label "While trazodone has only been FDA approved for use in the treatment of major depressive disorder, it has been used off label for numerous conditions including insomnia, anxiety, dementia, Alzheimer's disease, substance abuse, schizophrenia, bulimia, and fibromyalgia." assertion.
- context label "adults" assertion.
- association label "Two other sedating antidepressants, mirtazapine and trimipramine, are commonly used off-label for the treatment of ID without clear recommendations by any of the guidelines." assertion.
- DB00726 label "Trimipramine" assertion.
- DB00726 label "Trimipramine" assertion.
- context label "adults" assertion.
- association label "This paper describes current non-antibody pharmacologic approaches to the prevention of migraine in adults.(...) Several off-label drugs, especially lisinopril, candesartan, and amitriptyline also have good evidence of benefit." assertion.
- context label "adults" assertion.
- association label "This paper describes current non-antibody pharmacologic approaches to the prevention of migraine in adults.(...) Several off-label drugs, especially lisinopril, candesartan, and amitriptyline also have good evidence of benefit." assertion.
- DB13919 label "candesartan" assertion.
- context label "adults" assertion.
- association label "Other beta blockers, particularly metoprolol and atenolol, are used off‐label for migraine prevention." assertion.
- context label "adults" assertion.
- association label "Other beta blockers, particularly metoprolol and atenolol, are used off‐label for migraine prevention." assertion.
- context label "adults" assertion.
- association label "Other beta blockers, particularly metoprolol and atenolol, are used off‐label for migraine prevention." assertion.
- context label "adults" assertion.
- association label "Citalopram proved to be effective in the treatment of OCD [55], with best results at doses of 60 mg/day [56], which correlated with improvements on psychosocial functioning, depressive symptoms, obsessive thoughts, repetitive behavior, and anxiety. It showed good tolerability [57] and appeared to be effective in patients with refractory OCD [58]." assertion.
- association label "Sertraline has shown efficacy and safety at doses of 50-200 mg/day [72] in treating phobic-related states, with a greater reduction in symptoms related to anxiety/fear, physical symptoms and avoidance behaviors [73]. Clinical improvements in obsessive symptoms and phobic behavior have been achieved with long-term therapy, with a good tolerability profile. A rapid sertraline titration up to 200 mg/day correlated with fast response rates. A 20-week study with sertraline 50-200 mg/day produced significant improvements both in functioning and social skills [74]. Stable sertraline treatment guaranteed lower recurrence rates, and a general improvement in quality of life. Placebo-controlled studies consistently showed sertraline-related treatment response [72, 75, 76], although with one exception [77]. Treatment of refractory OCD with high doses of sertraline (250-400 mg/day) resulted in a significant symptom improvement and a similar rate of adverse events observed with a 200 mg/day dose [78]." assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "Ketamine has emerged as a rapid-acting antidepressant, though controversy remains whether sufficient data exist to justify its use outside of research protocols. In October 2014, the authors' institution began providing ketamine as an off-label therapy on a case-by-case basis for patients unable to participate in research protocols." assertion.
- association label "In some cases, this may be justifiable–for example, escitalopram is approved for treatment of generalized anxiety disorder, but its enantiomer, citalopram, is not [15]." assertion.
- context label "adults" assertion.
- context label "adults" assertion.
- association label "The most common off-label uses were for manic-depressive psychosis treated with citalopram and primary insomnia treated with trazodone." assertion.
- context label "adults" assertion.
- association label "For trazodone, the majority of off-label use was for insomnia (54.8%; 95% CI: 47.3–59.8) and anxiety disorders (45.0%; 95% CI: 36.6–52.4)" assertion.
- context label "adults" assertion.
- association label "Furthermore, the efficacy of trazodone in the treatment of primary insomnia or generalized anxiety disorders alone is weak, and the use of certain anti-depressants over FDA-approved benzodiazepines in anxiety disorders has been shown to be associated with a higher risk of adverse drug events [18, 32]." assertion.
- context label "adults" assertion.
- association label "The most common off-label uses were for manic-depressive psychosis treated with citalopram and primary insomnia treated with trazodone. Several patient and clinician characteristics were positively associated with off-label prescribing, including seeing a psychiatrist (OR: 1.06, 95% CI, 1.01–1.12; p = 0.03) instead of another type of clinician, the office visit taking place in the Western region of the country (OR: 1.09, 95% CI, 1.01–1.17; p = 0.02), and the patient having 3 or more chronic conditions (OR: 1.12, 95% CI, 1.02–1.14; p = 0.003)." assertion.
- context label "adults" assertion.
- association label "Information only available from Table 3" assertion.
- context label "adults" assertion.
- association label "Information only available from Table 3" assertion.
- context label "adults" assertion.
- association label "Anti-psychotics had the second highest rate of off-label prescription (28.6%)–the most common off-label use was for major depressive disorder." assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- association label "Information available in Table 3" assertion.
- context label "adults" assertion.
- association label "Studies have been conducted on both the main drugs used in alcohol dependence (NTX and ACA) and on the off-label drugs (topiramate, ondansetron, sertraline and olanzapine)." assertion.
- context label "adults" assertion.
- association label "Olanzapine was FDA approved for the treatment of schizophrenia and bipolar disorder only. It is an atypical antagonist of D2 and D4 receptors which determines a decrease in craving for alcohol. The DRD4 gene of dopamine presents a VNTR polymorphism, with a number of repetitions that varies from 2 to 11 which allows for the division of individuals in two subgroups: those with a number of repetitions between 2 and 6, classified as DRD4 S and those with more than 7 repetitions, classified as DRD4 L. Association studies between this variation and AUD have showed that individuals who carry the L allele exhibit greater craving after alcohol intake,50. Another study has investigated the association olanzapine-DRD4 showing that olanzapine reduces craving to the L allele carriers only, while no benefits were observed in S allele carriers." assertion.
- context label "adults" assertion.
- association label "The use of antidepressants to treat insomnia is widespread (Everitt 2014; Morlock 2006; NHS Digital 2011; Wilson 2010), but can be considered to be 'off‐label' as none is licensed for insomnia." assertion.
- context label "adults" assertion.
- association label "The use of antidepressants to treat insomnia is widespread (Everitt 2014; Morlock 2006; NHS Digital 2011; Wilson 2010), but can be considered to be 'off‐label' as none is licensed for insomnia." assertion.
- context label "adults" assertion.
- association label "The use of antidepressants to treat insomnia is widespread (Everitt 2014; Morlock 2006; NHS Digital 2011; Wilson 2010), but can be considered to be 'off‐label' as none is licensed for insomnia." assertion.
- context label "adults" assertion.
- association label "With this rapidly growing evidence of a fast-acting antidepressant such as ketamine, as well as its efficacy in treatment-resistant cases of depression, off-label use has become popular in certain settings." assertion.
- context label "adults" assertion.
- association label "Long-term prophylactic treatment relies on lithium, off-label use of valproate, and growing use of modern antipsychotics." assertion.
- context label "elderly" assertion.
- association label "Trazodone, the most sedating atypical antidepressant, is widely used as an off-label hypnotic especially in the elderly. Although generally considered safe, it can potentially inhibit midbrain dopaminergic neurotransmission leading to the emergence of extrapyramidal adverse effects. Two previous cases of trazodone-induced parkinsonism have been described after its prolonged use as an antidepressant; however, there is no published case of secondary parkinsonism caused by trazodone in a nondepressed person after its use as a hypnotic. Here, we present a case of rapid development of bradykinetic-rigid parkinsonism temporally linked to the use of trazodone as a hypnotic in a nondepressed elderly man" assertion.
- context label "adults" assertion.
- association label "While trazodone is approved for the treatment of depression, the off-label use of this medication for insomnia has surpassed its usage as an antidepressant." assertion.
- context label "children and adolescents" assertion.
- association label ""The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders." "The majority of children prescribed risperidone were diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) or conduct disorder."" assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. Table 1" assertion.
- context label "children and adolescents" assertion.
- association label "Antipsychotic medications are increasingly prescribed off-label to children for the treatment of disruptive behavior disorders, anxiety and depression." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders.(...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. Quetiapine was mainly prescribed for neurotic disorder or depression, while aripiprazole was prescribed most frequently for conduct disorder or neurotic disorders. (...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.
- association label "The majority of antipsychotic use in children in Alberta is off-label and associated with disruptive behavior disorders, depression, and anxiety disorders. (...) Information available in Table 1." assertion.
- context label "children and adolescents" assertion.